A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis-Reference-Cited by-同舟云学术

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis

Published:2018-03-28 Issue:6 Volume:29 Page:569-578
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Bilal Jawad¹^ORCID,Berlinberg Adam¹,Bhattacharjee Sandipan²,Trost Jaren¹,Riaz Irbaz Bin³,Kurtzman Drew J. B.⁴

Affiliation:

1. Department of Medicine, University of Arizona, Tucson, AZ, USA;

2. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA;

3. Department of General Internal Medicine, University of Arizona, Tucson, AZ, USA;

4. Division of Dermatology, University of Arizona, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2017.1422591

Reference47 articles.

1. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

2. The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients

3. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and ‘Type 1’ inflammatory gene expression

4. Das entz�ndliche Infiltrat bei Psoriasis vulgaris

5. Role of Dendritic Cells in Benign and Malignant Lymphocytic Infiltrates of the Skin

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab;JAAD International;2024-09

2. Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions;Frontiers in Cellular and Infection Microbiology;2024-08-07

3. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience;Actas Dermo-Sifiliográficas;2024-07

4. [Artículo traducido] Eficacia a medio plazo (52 semanas) de tildrakizumab en el tratamiento de la psoriasis moderada a severa: un estudio multicéntrico de práctica clínica;Actas Dermo-Sifiliográficas;2024-07

5. Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment;American Journal of Clinical Dermatology;2024-05-27